APA (7th ed.) Citation

V, O., N, M., L, A., M, E., S, N., N, A., . . . J, E. (2026). Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): A multicentre, single-arm, phase 2 trial. The Lancet. Haematology, 13(3), e133. https://doi.org/10.1016/S2352-3026(25)00328-X

Chicago Style (17th ed.) Citation

V, Ortiz-Maldonado, et al. "Varnimcabtagene Autoleucel for Adults with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukaemia in Spain (CART19-BE-02): A Multicentre, Single-arm, Phase 2 Trial." The Lancet. Haematology 13, no. 3 (2026): e133. https://doi.org/10.1016/S2352-3026(25)00328-X.

MLA (9th ed.) Citation

V, Ortiz-Maldonado, et al. "Varnimcabtagene Autoleucel for Adults with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukaemia in Spain (CART19-BE-02): A Multicentre, Single-arm, Phase 2 Trial." The Lancet. Haematology, vol. 13, no. 3, 2026, p. e133, https://doi.org/10.1016/S2352-3026(25)00328-X.